The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

More information: Robert Wood et al, Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi ...

Omalizumab, currently used to treat asthma, has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food ...

87.3% of white patients and 92.8% of Black patients had no severe exacerbations with omalizumab. 4% of white patients and 2.9% of Black patients had a serious adverse event with omalizumab.

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

Regular use of the injectable drug, omalizumab, marketed under the brand name Xolair, targets inflammation by binding and inactivating antibodies that cause many kinds of allergic disease.

Director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, Robert Wood, MD led a clinical trial on omalizumab — an already FDA-approved drug ...

The approval was based on results from a phase III trial that confirmed the bioequivalence of the biosimilar, formerly known as CT-P39, to omalizumab in patients with chronic spontaneous urticaria.

Robert Wood, the director of the Eudowood Division of Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, led a clinical trial on omalizumab—an already FDA-approved drug ...